- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03953989
Effects of Ranolazine on Coronary Microvascular Dysfunction in Patients With Hypertrophic Cardiomyopathy
A Pilot Study Assessing the Effects of Ranolazine on Coronary Microvascular Dysfunction in Patients With Hypertrophic Cardiomyopathy
Study Overview
Status
Intervention / Treatment
Detailed Description
This pilot study aimed at assessing the effects of treatment with ranolazine, on top of optimal standard medical therapy (according to international guidelines), on microvascular dysfunction using PET in patients with HCM.
Thirty months of enrolment are foreseen. Patients enrolled in the study, at the end of the titration phase will be treated with ranolazine 750 mg or 500 mg, 1 oral tablet twice a day for 4 months on top of standard of care treatment. Visit 0,1,2,3 may be performed 3 days before or 3 days after the planned date. Visit 4 and final PET scan may be performed 15 days before or 15 days after the planned date.
This is a superiority study. The sample size calculation is based on the ANOVA model, but the statistical analysis will be performed applying the ANCOVA model for the absence of data on the correlation between basal and end of study values of the primary variable studied. As previously reported (Camici et al. J Am Coll Cardiol 1991; 17:879-86) maximum (i.e. during dipyridamole stress) MBF is severely blunted in HCM (1.63±0.58 mL/min/g) compared to control subjects (2.99±1.06 mL/min/g). For the primary end-point of the study using a two-sided test at 5% significance level, with a power of 90% and a SD of ± 0.7 mL/min/gr, in order to detect a change of 0.5 mL/min/gr in maximum MBF before and after treatment, 24 patients valid per protocol are required.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Milan, Italy, 20132
- IRCCS Ospedale San Raffaele
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female gender (females of childbearing potential must be using highly effective contraceptive precautions such as implants, injectables, combined oral contraceptives, intrauterine devices, sexual abstinence or vasectomised partner);
- Females of childbearing potential or within two years from the menopause must have a negative urine pregnancy test;
- Patients which fulfill conventional echocardiographic criteria for the diagnosis of HCM: maximum LV wall thickness ≥ 15 mm;
- Patients aged > 18 years and < 80 years;
- Sinus rhythm accepted isolated Supraventricular and Ventricular Premature Beats (VPB);
- Absence of severe resting LV outflow tract obstruction (peak gradient ≤ 50 mmHg);
- Written informed consent prior to enrolment into the study;
Exclusion Criteria:
- Females of childbearing potential not using highly effective contraceptive precautions;
- Presence of known coronary artery disease (CAD);
- Presence of Chronic Obstructive Airways Disease;
- Asthma;
- Other causes of microvascular dysfunction including long-standing history of arterial hypertension, diabetes, uncontrolled dyslipidemia;
- Body mass index >32 kg/m2; < 17 kg/m2
- Overt LV systolic dysfunction with end-stage progression (LV-EF <50%);
- Concomitant administration of potent CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, voriconazol, posaconazol, HIV protease inhibitors, clarithromycin, telithromycin, nefazodone);
- Patients treated with sotalol, dronedarone, class I antiarrhythmics (see appendix 4) or other QT-prolonging drugs; stable treatment with amiodarone is permitted;
- Patients with QTc (Bazett's formula) at baseline ≥ 450 ms males; ≥470 msec females;
- Any clinically relevant haematological or biochemical abnormality on routine screening, according to Investigator's judgment;
- Severe concurrent pathology, including terminal illness (cancer, AIDS, etc.);
- Severe renal impairment defined as GFR < 29 mL/min/1.73m2 or creatinine level > 2.5 mg/dL or BUN >60 mg/dL;
- Moderate or severe hepatic impairment or hepatic insufficiency defined as SGOT or SGPT > 2 times greater than normal upper limit of the local laboratory or total serum bilirubin > 1.5 times greater than normal upper limit of the local laboratory;
- Dementia, psychosis, alcoholism (>350 g ethanol/week) or chronic abuse of medicaments, drugs or psychoactive substances;
- Claustrophobia;
- Females who are pregnant or lactating;
- Conditions that in the Investigator's opinion may interfere with the study's execution or due to which the patient should not participate for safety reasons;
- Risk of poor patient cooperation;
- Participation in a clinical study ≤ 2 months before enrolment;
- Inability or unwillingness to issue the informed consent;
- Concomitant use of > 20 mg daily dose of Simvastatin during the study (in case of patients taking simvastatin > 20 mg daily, the switch to other statins not metabolized by the CYP3A4 could be considered);
- Concomitant use of Atorvastatin (> 80 mg daily)
- Concomitant use of > 1000 mg daily dose of metformin during the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients with hypertrophic cardiomyopathy
Thestudy is articulated into Screening visit plus other 3 visits. One visit (V2 ) for dose titration. V0 screening eligibility, consent, Medical History, physical examination, BP, ECG, Echocardiography, Biochemistry (haematology, electrolytes, glycaemia, ALS and bilirubin, creatinine and urine-analysis) V1 Baseline PET scan, physical examination, vital signs, and drug supply (500 mg bid). V2 physical examination, safety check, biochemistry, drug compliance and up-titration (750 mg bid), drug supply. V3 (2 months)safety check ,drug supply, drug compliance V4 (4 months, end of treatment) repeat PET scan, physical examination, BP, ECG, drug compliance, safety. Drug of the study Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die |
Patients enrolled in the study, at the end of the titration phase will be treated with ranolazine 750 mg or 500 mg, 1 oral tablet twice a day for 4 months on top of standard of care treatment
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Myocardial Blood Flow during hyperemia ml/min/g
Time Frame: At baseline and after 4 months of treatment
|
Change of near maximal hyperemic myocardial blood flow (MBF ml/min/g) after treatment with ranolazine of at least 0.5 ml/min/g.
Myocardial perfusion measured with 13N-ammonia and positron emission tomography at rest and during hyperemia; Hyperaemic Myocardial Blood Flow (MBF) measured following i.v.
dipyridamole (0.56 mg/Kg in 4 mins)
|
At baseline and after 4 months of treatment
|
Coronary Flow Reserve (hyperaemic MBF /resting MBF = CFR).
Time Frame: At baseline and after 4 months of treatment
|
Change of CFR after treatment with ranolazine for four months
|
At baseline and after 4 months of treatment
|
Coronary resistance
Time Frame: At baseline and after 4 months of treatment
|
Change of Resting coronary resistance (Mean Arterial Pressure rest/ MBF rest) and minimal (during hyperemia) coronary resistance (Mean arterial Pressure hyperemia/ MBF hyperemia)
|
At baseline and after 4 months of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Symptoms
Time Frame: through 4 month of treatment
|
Number of participants with absence of symptoms accountable for drug intolerability ,assessed through customized questionnaire.
If symptoms are accountable for drug intolerability are referred, the patient will come back to 500 mg/bid.
|
through 4 month of treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Paolo Camici, MD, IRCCS Ospedale San Raffaele
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Pathological Conditions, Anatomical
- Aortic Valve Disease
- Heart Valve Diseases
- Aortic Stenosis, Subvalvular
- Aortic Valve Stenosis
- Hypertrophy
- Cardiomyopathies
- Cardiomyopathy, Hypertrophic
- Molecular Mechanisms of Pharmacological Action
- Membrane Transport Modulators
- Sodium Channel Blockers
- Ranolazine
Other Study ID Numbers
- HCMRanIT001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HCM - Hypertrophic Non-Obstructive Cardiomyopathy
-
University Hospital HeidelbergCharite University, Berlin, Germany; Goethe University; University Medicine Greifswald and other collaboratorsRecruitingAmyloidosis | HCM - Hypertrophic Cardiomyopathy | Arrhythmogenic Right Ventricular Cardiomyopathy | Inflammatory Cardiomyopathy | DCM - Dilated Cardiomyopathy | Non-ischemic Cardiomyopathy | HOCM - Hypertrophic Obstructive Cardiomyopathy | Left Ventricular Noncompaction CardiomyopathyGermany
-
Bristol-Myers SquibbActive, not recruitingHypertrophic Cardiomyopathy (HCM)United States
-
CytokineticsEnrolling by invitationSymptomatic Hypertrophic Cardiomyopathy (HCM)United States, France, Israel, Spain, United Kingdom, Italy, Poland, Hungary, Denmark, Netherlands, Germany, Czechia, Portugal
-
Guangdong Provincial People's HospitalRecruitingHCM - Hypertrophic CardiomyopathyChina
-
CytokineticsCompletedHypertrophic Cardiomyopathy (HCM)United States, Spain, Italy, Netherlands
-
University of Sao PauloCompletedNon-obstructive Hypertrophic Cardiomyopathy | Obstructive Hypertrophic CardiomyopathyBrazil
-
French Cardiology SocietyCompleted1- Primary (Sarcomeric) Hypertrophic Cardiomyopathy | 2- Obstructive Hypertrophic Cardiomyopathy | 3- Non Obstructive Hypertrophic CardiomyopathyFrance
-
Bristol-Myers SquibbActive, not recruitingHypertrophic Cardiomyopathy | Non-obstructive Hypertrophic Cardiomyopathy | Obstructive Hypertrophic CardiomyopathyDenmark, United States, Belgium, Czechia, France, Germany, Israel, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHypertrophic Cardiomyopathy (HCM)United States
-
MyoKardia, Inc.CompletedNon-obstructive Hypertrophic CardiomyopathyUnited States
Clinical Trials on Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die
-
BiocodexRecruitingChronic Renal InsufficiencyBulgaria
-
GlaxoSmithKlineTerminated
-
Federico II UniversityCompletedDiabetes Mellitus | Acute Coronary SyndromeItaly
-
Medical College of WisconsinWithdrawnRefractory Multiple Myeloma | Relapse Multiple Myeloma
-
Breath of Life International Pharma LtdCompleted
-
NobelpharmaCompleted
-
Kirby InstituteActive, not recruitingHIV InfectionsMalaysia, Zimbabwe, India, South Africa, Thailand
-
Fundacion Clinic per a la Recerca BiomédicaUnknown
-
Gilead SciencesCompletedHepatitis CUnited States, Puerto Rico
-
Hospital for Special Surgery, New YorkCompletedTotal Hip ReplacementUnited States